RE:RE:Takeover/BuyoutWe have been in a situation that RDW and his team have been repeating the same thing over and over. Initially it was that they did not present the data the way that FDA required. I get it, now they hired consultants to get the data streamlined and present to FDA that they can compare with our competitors. Now if you tell me that the newly hired consultants did not present the data correctly? or the FDA finds another excuse for granting BTD we have a serious problem with recognition and Big pharma control over FDA. I don't think RDW can navigate this road block on his own. I would certainly Vote in favour of a new management if we can get a fair enough offer. What I think is fair is not that relevant. I think ONE Merck share for 10 TLT share would recognise our potential value. Who knows the real story behind the scene that TLT is not willing to disclose.